Exegenesis Bio Inc.

Develops gene therapies and oligonucleotide therapeutics for neurological and ophthalmic diseases, with a nine-candidate pipeline including treatments for wet AMD and SMA Type 1 in clinical trials in China and the United States.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Social insurance & housing fund
• Intellectual property
• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Connected or related major customers / suppliers
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Related-party transactions and balances
• Chapter 18A biotech